MetaVia公司在2026年欧洲肝脏研究学会(EASL)大会上,公布了其候选药物DA-1726更高剂量组的一期临床试验结果。新数据进一步支持了该药物在治疗肥胖及代谢相关脂肪性肝炎(MASH)方面的潜在应用价值。
MetaVia公司在2026年欧洲肝脏研究学会(EASL)大会上,公布了其候选药物DA-1726更高剂量组的一期临床试验结果。新数据进一步支持了该药物在治疗肥胖及代谢相关脂肪性肝炎(MASH)方面的潜在应用价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.